Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by the School of Health and Related Research (ScHARR), University of Sheffield:

  • Jackson R et al. (2010) Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying anti-rheumatic drugs: a single technology appraisal. September 2010

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • MSD

II Professional/specialist and patient/carer groups:

  • National Rheumatoid Arthritis Society

  • British Health Professionals in Rheumatology

  • British Society for Rheumatology

  • Primary Care Rheumatology Society

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • Northumberland Care Trust

  • Torbay Care Trust

  • Welsh Assembly Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • NHS Quality Improvement Scotland

  • Abbott Laboratories (adalimumab)

  • AstraZeneca UK

  • Bristol Myers Squibb

  • Pfizer

  • Roche Products

  • Sanofi Aventis

  • MSD

  • UCB Pharma

  • National Institute for Health Research Health Technology Assessment Programme

  • School of Health & Related Research Sheffield (ScHARR)

  • National Clinical Guideline Centre (NCGC)

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on Golimumab for the treatment of rheumatoid arthritis after failure of previous disease-modifying anti-rheumatic drugs by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Chris Deighton, Consultant Rheumatologist, nominated by National Clinical Guideline Centre – clinical specialist

  • Professor Rob Moots, Professor of Rheumatology, nominated by British Society for Rheumatology

  • Jean Burke, nominated by National Rheumatoid Arthritis Society – patient expert

  • Adrienne Yarwood, nominated by National Rheumatoid Arthritis Society – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • MSD

  • National Institute for Health and Care Excellence (NICE)